Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 70 articles: HTML format

Single Articles

September 2025
1. ZHAO Z, Rong H, Li M, Xu Y, et al
   Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.
   Int J Cancer. 2025 Sep 13. doi: 10.1002/ijc.70153.
   PubMed     Abstract available
   
   
   
2. XU Y, Zhang Q, Gao J, Yao S, et al
   Effects of immune checkpoint inhibitors on the pulmonary circulation in lung cancer patients.
   Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70110.
   PubMed     Abstract available
   
   
   
3. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   PubMed     Abstract available
   
   
   
4. SUN Y, Deng Z, Sun H, Wei X, et al
   Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis.
   Int J Cancer. 2025;157:916-926.
   PubMed     Abstract available
   
   
   
5. KANNO C, Kojima M, Watanabe Y, Honda R, et al
   Molecular targeted drugs affect the development of antiresorptive-related osteonecrosis of the jaw in patients with lung and kidney cancers.
   Int J Cancer. 2025;157:890-896.
   PubMed     Abstract available
   
   
   
6. CHEN T, Wang W, Qian Y, Wang M, et al
   Immune checkpoint inhibitors combined with anti-angiogenic therapy as second- or further-line treatment for small cell lung cancer: Efficacy, safety, and prognostic biomarkers.
   Int J Cancer. 2025 Sep 1. doi: 10.1002/ijc.70102.
   PubMed     Abstract available
   
   
   August 2025
7. ZHANG Q, Fu Q, Hou Y, Lv Y, et al
   Advances in CAR-T therapy for small cell lung cancer.
   Int J Cancer. 2025 Aug 18. doi: 10.1002/ijc.70093.
   PubMed     Abstract available
   
   
   
8. LI W, Pan S, Qian J, Xia Y, et al
   Comparisons of blood, upper respiratory tract and gut viromes from patients with lung cancer and healthy persons.
   Int J Cancer. 2025 Aug 8. doi: 10.1002/ijc.70075.
   PubMed     Abstract available
   
   
   
9. ZHONG R, Chu T, Xiong L, Shi C, et al
   Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study.
   Int J Cancer. 2025;157:549-558.
   PubMed     Abstract available
   
   
   July 2025
10. DE VRIES F, Otten LS, Piet B, Franssen EJF, et al
    Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.
    Int J Cancer. 2025 Jul 24. doi: 10.1002/ijc.70052.
    PubMed     Abstract available
    
    
    
11. DU Y, Yuan C, Ni X, Miao J, et al
    Overdiagnosis in low-dose CT lung cancer screening: A systematic review and meta-analysis of overall magnitude and subgroup variations.
    Int J Cancer. 2025 Jul 18. doi: 10.1002/ijc.70049.
    PubMed     Abstract available
    
    
    
12. DE NIJS K, Ten Haaf K, Hubert J, Moldovanu D, et al
    Stage- and histology-specific sensitivity for the detection of lung cancer of the NELSON screening protocol-A modeling study.
    Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70045.
    PubMed     Abstract available
    
    
    
13. DENG Y, Guo C, Zhang T, Chen Y, et al
    Comprehensive analysis of a real-world cohort identifies geranylgeranyl diphosphate synthase 1 as a predictor of chemoresistance in small cell lung cancer.
    Int J Cancer. 2025 Jul 4. doi: 10.1002/ijc.70036.
    PubMed     Abstract available
    
    
    June 2025
14. WANG K, Xiang J, Zhou J, Chen C, et al
    Development and validation of a transcription factor regulatory network-based signature for individualized prognostic risk in lung adenocarcinoma.
    Int J Cancer. 2025;156:2440-2451.
    PubMed     Abstract available
    
    
    
15. CHANG GC, Kapoor A, Lee CK, Su C, et al
    Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.
    Int J Cancer. 2025 Jun 14. doi: 10.1002/ijc.35512.
    PubMed     Abstract available
    
    
    
16. ZHAO R, Lu H, Yuan H, Chen S, et al
    Plasma proteomic profiles for early detection and risk stratification of non-small cell lung carcinoma: A prospective cohort study with 52,913 participants.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35518.
    PubMed     Abstract available
    
    
    April 2025
17. XIE Y, Fang H, Cheng W, Xu T, et al
    Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460.
    PubMed     Abstract available
    
    
    
18. TSURUDA KM, Hektoen HH, Aamelfot C, Andreassen BK, et al
    Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445.
    PubMed     Abstract available
    
    
    
19. NOFAL S, J Ostrin E, Zhang J, Wu J, et al
    Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35452.
    PubMed     Abstract available
    
    
    
20. DIAO M, Wang Y, Wu S, He S, et al
    Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.
    Int J Cancer. 2025;156:1501-1508.
    PubMed     Abstract available
    
    
    
21. NOMURA K, Takada K, Kinoshita F, Muto S, et al
    Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
    Int J Cancer. 2025;156:1480-1491.
    PubMed     Abstract available
    
    
    March 2025
22. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
    Sex specific familial risk in lung cancer through changing histologies in Sweden.
    Int J Cancer. 2025 Mar 29. doi: 10.1002/ijc.35431.
    PubMed     Abstract available
    
    
    February 2025
23. XU H, Fu X, Wang S, Ge Y, et al
    Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.
    Int J Cancer. 2025 Feb 5. doi: 10.1002/ijc.35360.
    PubMed     Abstract available
    
    
    January 2025
24. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    PubMed     Abstract available
    
    
    
25. KANZAKI R, Reid S, Bolivar P, Sjolund J, et al
    FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma.
    Int J Cancer. 2025;156:431-446.
    PubMed     Abstract available
    
    
    
26. LAZZARI N, Rigotto G, Montini B, Del Bianco P, et al
    Stemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei.
    Int J Cancer. 2025;156:201-215.
    PubMed     Abstract available
    
    
    December 2024
27. CHEI CL, Nakamura S, Watanabe K, Mizutani T, et al
    Assessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35316.
    PubMed     Abstract available
    
    
    
28. LU G, Liu H, Wang H, Luo S, et al
    Genetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35305.
    PubMed     Abstract available
    
    
    
29. YANG ZM, Qin XY, Lu YY, Yao LK, et al
    Pathogen spectrum and clinical characteristics of lung cancer patients: A 10-year retrospective study.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35272.
    PubMed     Abstract available
    
    
    
30. BRANCO H, Rodrigues CA, Oliveira J, Mendes N, et al
    Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.
    Int J Cancer. 2024 Dec 4. doi: 10.1002/ijc.35276.
    PubMed     Abstract available
    
    
    November 2024
31. BURUS T, Patel MI, Christian WJ, Huang B, et al
    Sex-based differences in histologic lung cancer incidence trends in the United States, 2005-2019.
    Int J Cancer. 2024 Nov 21. doi: 10.1002/ijc.35268.
    PubMed     Abstract available
    
    
    
32. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    PubMed     Abstract available
    
    
    
33. TAKADA K, Takamori S, Shimokawa M, Pinato DJ, et al
    Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35249.
    PubMed     Abstract available
    
    
    October 2024
34. JEMAL A, Schafer EJ, Star J, Bandi P, et al
    Lung cancer incidence rates in young women and men by state in the United States.
    Int J Cancer. 2024 Oct 11. doi: 10.1002/ijc.35188.
    PubMed     Abstract available
    
    
    
35. MA Z, Zhu Z, Pang G, Gong F, et al
    Development and validation of a lung cancer polygenic risk score incorporating susceptibility variants for risk factors.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35210.
    PubMed     Abstract available
    
    
    
36. KISHIDA R, Yin X, Abe SK, Rahman MS, et al
    Association between family history with lung cancer incidence and mortality risk in the Asia Cohort Consortium.
    Int J Cancer. 2024 Oct 3. doi: 10.1002/ijc.35191.
    PubMed     Abstract available
    
    
    September 2024
37. HU H, Zhu Q, Tang H, Zhang SC, et al
    The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35195.
    PubMed     Abstract available
    
    
    
38. WANG H, Liu H, Tang X, Lu G, et al
    Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35197.
    PubMed     Abstract available
    
    
    
39. WIESWEG M, Kuter C, Schnorbach J, Keyl J, et al
    Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35199.
    PubMed     Abstract available
    
    
    August 2024
40. SCHULTE C, Gauler T, Pottgen C, Friedel G, et al
    Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).
    Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35131.
    PubMed     Abstract available
    
    
    
41. CHEN S, Cheng S, Cai J, Liu Z, et al
    The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
    Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088.
    PubMed     Abstract available
    
    
    July 2024
42. PULAWSKA-MOON K, Ponikwicka-Tyszko D, Lebiedzinska W, Pilaszewicz-Puza A, et al
    Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth.
    Int J Cancer. 2024 Jul 22. doi: 10.1002/ijc.35098.
    PubMed     Abstract available
    
    
    
43. BRATIVNYK A, Ankill J, Helland A, Fleischer T, et al
    Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
    Int J Cancer. 2024;155:282-297.
    PubMed     Abstract available
    
    
    
44. YIN M, Liu L, Yan Y, Wang H, et al
    A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35065.
    PubMed     Abstract available
    
    
    
45. ZHANG Q, Chen K, Yu X, Fan Y, et al
    Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.
    Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35070.
    PubMed     Abstract available
    
    
    June 2024
46. MELOSKY B, Vincent MD, McGuire AL, Brade AM, et al
    Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
    Int J Cancer. 2024 Jun 20. doi: 10.1002/ijc.35031.
    PubMed     Abstract available
    
    
    
47. ZHANG B, Li C, Wu J, Zhang J, et al
    DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.
    Int J Cancer. 2024;154:2151-2161.
    PubMed     Abstract available
    
    
    
48. CHEN C, Zhou X, Gao X, Pan R, et al
    Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Int J Cancer. 2024 Jun 5. doi: 10.1002/ijc.35038.
    PubMed     Abstract available
    
    
    
49. GU Z, Huang P, Zhao J, Luo C, et al
    Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
    Int J Cancer. 2024;154:1979-1986.
    PubMed     Abstract available
    
    
    
50. SEBASTIAN M, Eberhardt WEE, von der Heyde E, Dorfel S, et al
    Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
    Int J Cancer. 2024;154:1967-1978.
    PubMed     Abstract available
    
    
    May 2024
51. MIYAMORI D, Kamitani T, Yoshida S, Kikuchi Y, et al
    Effects of the Coronavirus disease 2019 pandemic on mortality in patients with lung cancer: A multiple mediation analysis in Japan.
    Int J Cancer. 2024 May 24. doi: 10.1002/ijc.35042.
    PubMed     Abstract available
    
    
    
52. WANG Z, Zhang Q, Wang C, Herth FJF, et al
    Multiple primary lung cancer: Updates and perspectives.
    Int J Cancer. 2024 May 23. doi: 10.1002/ijc.34994.
    PubMed     Abstract available
    
    
    
53. KOURO T, Higashijima N, Horaguchi S, Mano Y, et al
    Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
    Int J Cancer. 2024;154:1828-1841.
    PubMed     Abstract available
    
    
    April 2024
54. RAHMAN ML, Shu XO, Jones DP, Hu W, et al
    A nested case-control study of untargeted plasma metabolomics and lung cancer among never-smoking women within the prospective Shanghai Women's Health Study.
    Int J Cancer. 2024 Apr 23. doi: 10.1002/ijc.34929.
    PubMed     Abstract available
    
    
    
55. MULSHINE JL, Avila RS, Rizzo AA, Estepar RSJ, et al
    Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to optimize population health final summary.
    Int J Cancer. 2024;154:1365-1370.
    PubMed     Abstract available
    
    
    March 2024
56. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available
    
    
    February 2024
57. YIN X, Kishida R, Abe SK, Islam MR, et al
    Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia cohort consortium.
    Int J Cancer. 2024 Feb 20. doi: 10.1002/ijc.34866.
    PubMed     Abstract available
    
    
    
58. WELSCH E, Holzer B, Schuster E, Fabikan H, et al
    Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation.
    Int J Cancer. 2024 Feb 14. doi: 10.1002/ijc.34886.
    PubMed     Abstract available
    
    
    January 2024
59. MORITA A, Ichihara E, Inoue K, Fujiwara K, et al
    Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34842.
    PubMed     Abstract available
    
    
    
60. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    
61. KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer. 2024;154:169-179.
    PubMed     Abstract available
    
    
    December 2023
62. MORISUE R, Kojima M, Suzuki T, Watanabe R, et al
    Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study.
    Int J Cancer. 2023;153:1997-2010.
    PubMed     Abstract available
    
    
    November 2023
63. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    PubMed     Abstract available
    
    
    
64. PELOS G, Riester M, Pal J, Myacheva K, et al
    Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment.
    Int J Cancer. 2023 Nov 10. doi: 10.1002/ijc.34783.
    PubMed     Abstract available
    
    
    October 2023
65. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    PubMed     Abstract available
    
    
    
66. WEI X, Sun D, Gao J, Zhang J, et al
    Development and evaluation of a polygenic risk score for lung cancer in never-smoking women: A large-scale prospective Chinese cohort study.
    Int J Cancer. 2023 Oct 17. doi: 10.1002/ijc.34765.
    PubMed     Abstract available
    
    
    
67. VAN VEELEN A, Veerman GDM, Verschueren MV, Gulikers JL, et al
    Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34742.
    PubMed     Abstract available
    
    
    
68. YU Z, Ni P, Yu H, Zuo T, et al
    Effectiveness of a single low-dose computed tomography screening for lung cancer: A population-based perspective cohort study in China.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34741.
    PubMed     Abstract available
    
    
    
69. TOMONAGA Y, de Nijs K, Bucher HC, de Koning H, et al
    Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34746.
    PubMed     Abstract available
    
    
    September 2023
70. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.